Literature DB >> 20471854

In vitro cytokine release assays for predicting cytokine release syndrome: the current state-of-the-science. Report of a European Medicines Agency Workshop.

Jean-Marc Vidal1, Thomas T Kawabata, Robin Thorpe, Beatriz Silva-Lima, Karin Cederbrant, Stephen Poole, Jan Mueller-Berghaus, Marc Pallardy, Jan-Willem Van der Laan.   

Abstract

Mesh：

Substances：

Year:  2010        PMID： 20471854     DOI： 10.1016/j.cyto.2010.04.008

Source DB:  PubMed          Journal:  Cytokine        ISSN： 1043-4666            Impact factor:   3.861


× No keyword cloud information.
  11 in total

1.  Development of the first reference antibody panel for qualification and validation of cytokine release assay platforms - Report of an international collaborative study.

Authors:  Sandrine Vessillier; Madeline Fort; Lynn O'Donnell; Heather Hinton; Kimberly Nadwodny; Joseph Piccotti; Peter Rigsby; Karin Staflin; Richard Stebbings; Divya Mekala; Aarron Willingham; Babette Wolf
Journal:  Cytokine X       Date:  2020-12

2.  Advantages of Papio anubis for preclinical testing of immunotoxicity of candidate therapeutic antagonist antibodies targeting CD28.

Authors:  Nicolas Poirier; Caroline Mary; Stephanie Le Bas-Bernardet; Veronique Daguin; Lyssia Belarif; Melanie Chevalier; Jeremy Hervouet; David Minault; Simon Ville; Vianney Charpy; Gilles Blancho; Bernard Vanhove
Journal:  MAbs       Date:  2014-03-05       Impact factor: 5.857

3.  Biosimilars entering the clinic without animal studies. A paradigm shift in the European Union.

Authors:  Leon A G J M van Aerts; Karen De Smet; Gabriele Reichmann; Jan Willem van der Laan; Christian K Schneider
Journal:  MAbs       Date:  2014       Impact factor: 5.857

4.  Cytokine release assays for the prediction of therapeutic mAb safety in first-in man trials--Whole blood cytokine release assays are poorly predictive for TGN1412 cytokine storm.

Authors:  S Vessillier; D Eastwood; B Fox; J Sathish; S Sethu; T Dougall; S J Thorpe; R Thorpe; R Stebbings
Journal:  J Immunol Methods       Date:  2015-05-07       Impact factor: 2.303

5.  MDCO-216 Does Not Induce Adverse Immunostimulation, in Contrast to Its Predecessor ETC-216.

Authors:  Joannes A A Reijers; D G Kallend; K E Malone; J W Jukema; P L J Wijngaard; J Burggraaf; M Moerland
Journal:  Cardiovasc Drugs Ther       Date:  2017-08       Impact factor: 3.727

Review 6.  COVID-19: Clinical laboratory diagnosis and monitoring of novel coronavirus infected patients using molecular, serological and biochemical markers: A review.

Authors:  Ghulam Rasool; Muhammad Riaz; Mazhar Abbas; Hina Fatima; Muhammad Mustafa Qamar; Farzana Zafar; Zahed Mahmood
Journal:  Int J Immunopathol Pharmacol       Date:  2022 Jan-Dec       Impact factor: 3.298

Review 7.  Prediction and prevention of the next pandemic zoonosis.

Authors:  Stephen S Morse; Jonna A K Mazet; Mark Woolhouse; Colin R Parrish; Dennis Carroll; William B Karesh; Carlos Zambrana-Torrelio; W Ian Lipkin; Peter Daszak
Journal:  Lancet       Date:  2012-12-01       Impact factor: 79.321

Review 8.  Clinical development methodology for infusion-related reactions with monoclonal antibodies.

Authors:  Lucette Doessegger; Maria Longauer Banholzer
Journal:  Clin Transl Immunology       Date:  2015-07-17

9.  Immunotoxicity assessment of rice-derived recombinant human serum albumin using human peripheral blood mononuclear cells.

Authors:  Kai Fu; Qin Cheng; Zhenwei Liu; Zhen Chen; Yan Wang; Honggang Ruan; Lu Zhou; Jie Xiong; Ruijing Xiao; Shengwu Liu; Qiuping Zhang; Daichang Yang
Journal:  PLoS One       Date:  2014-08-06       Impact factor: 3.240

Review 10.  Challenges and approaches for the development of safer immunomodulatory biologics.

Authors:  Jean G Sathish; Swaminathan Sethu; Marie-Christine Bielsky; Lolke de Haan; Neil S French; Karthik Govindappa; James Green; Christopher E M Griffiths; Stephen Holgate; David Jones; Ian Kimber; Jonathan Moggs; Dean J Naisbitt; Munir Pirmohamed; Gabriele Reichmann; Jennifer Sims; Meena Subramanyam; Marque D Todd; Jan Willem Van Der Laan; Richard J Weaver; B Kevin Park
Journal:  Nat Rev Drug Discov       Date:  2013-04       Impact factor: 112.288
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.